Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-06-03Actual
Enrollment · participants432Actual
Source updated2025-07-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.